Skip to main content

Tempus AI signals beyond the news: 70+ signals from 7 sources

The latest Tempus AI signal on this page is from Oct 27, 2026 (Patents): "Tempus AI was granted a patent for extracting clinical phenotypes from notes." The busiest sources: Glassdoor (15+), LinkedIn (15+) and Website changes (15+).

Public (TEM)Biotechnology Research5,001 to 10,000 employeestempus.comLinkedIn

Get Tempus AI's live signals in Claude or ChatGPT, or by API

AskWhat changed at Tempus AI this week? Use Autobound signals for tempus.com.
Signals
70+
Sources
7
Last 90 days
27
Latest
Oct 27, 2026

Source: Autobound Signal API · 98 signals tracked for Tempus AI · updated

Other signals · latest 10

Latest Tempus AI signals by source

70+ signals for Tempus AI across 7 sources.

  1. Patents · Patent grant

    Tempus AI was granted a patent for extracting clinical phenotypes from notes.

    In October 2026 Tempus AI patented natural-language processing for identifying condition-related information in unstructured EHR and EMR notes for clinical data analysis.

    Patent title
    Phenotyping of clinical notes using natural language processing models
    Grant date
    Oct 27, 2026
    Inventors
    William E. Thompson, IV, David Michael Vidmar, RuiJun Chen
    Tech area
    health tech / medical informatics

    Google Patents

  2. Patents · Patent pace

    TEMPUS AI, INC.'s patent output is slowing: 24 grants in the past year, 1 in the past 30 days.

    Over the past year TEMPUS AI, INC. received 24 US patent grants, concentrated in health tech / medical informatics and software / computing; the recent pace (7 in 90 days) is slowing versus its trailing baseline.

    Grants, 12 months
    24
    Grants, 90 days
    7
    Grants, 30 days
    1
    Pace
    Decelerating

    Google Patents

  3. Glassdoor · Compensation dissatisfaction

    Employees report low associate pay and compensation below market rate

    Multiple reviewers mention that associate pay is tough and compensation is slightly under market rate, impacting overall satisfaction.

    Overall rating
    3.1 of 5
    CEO approval
    44%
    Reviews read
    9
    Review window
    Sep 11, 2026 to Oct 10, 2026

    Glassdoor

  4. Glassdoor · Engineering culture issues

    Senior Software Engineer describes terrible engineering culture plagued by politics and incompetence

    A Senior Software Engineer reports an engineering culture rife with politics and incompetence, criticizing non-engineers in leadership roles and bureaucratic processes that hinder progress.

    Overall rating
    3.1 of 5
    CEO approval
    44%
    Reviews read
    9
    Review window
    Sep 11, 2026 to Oct 10, 2026

    Glassdoor

  5. Product reviews · Pricing concerns

    Verified User reports Tempus is expensive to use despite being cost-effective

    A Verified User in Computer & Network Security at a Small-Business company notes that Tempus is expensive to use, although they deem it cost-effective overall. This indicates a potential barrier for some users or a concern regarding the cost-to-value ratio.

    Star rating
    4 of 5
    Reviewer
    Verified User in Computer & Network Security
    Reviewer details
    Small-Business (50 or fewer emp.)

    g2.com

  6. Reddit · Acquisition announced

    Tempus has an agreed buyout offer to acquire Personalis at $16.25 per share, which is pending shareholder approval.

    Post: "PSNL - a textbook case of reflexivity from Soros’ Alchemy of Finance?"

    Subreddit
    r/wallstreetbets
    Upvotes
    1
    Comments
    0
    Sentiment
    Neutral

    r/wallstreetbets

  7. LinkedIn

    Tempus CEO discusses unified stack for drug development with AI integration.

    In a new article, our CEO of Data & Apps, Ryan Fukushima, shares his perspective on why drug development requires a unified stack • Proprietary Multimodal Data to capture actual biology • Tailored AI Models & Agents to perform multi-step scientific reasoning • High-Performance Compute brought directly to the data...

    Likes
    47
    Comments
    1
    Tags
    Artificial Intelligence, Product Development, Research & Development, Pharmaceuticals
    Initiatives
    integrating AI into drug development platform

    LinkedIn

  8. Product reviews · Missing features

    SREs report Tempus lacks customization for dashboards, reporting, and workflow automation

    Atharva S., an SRE at a mid-market company, expresses a need for more customization for dashboards, reporting, and workflow automation. A Verified User from a mid-market internet company also desires more customization options for dashboards and data visualizations.

    Star rating
    4.5 of 5
    Reviewer
    Atharva S.

    g2.com

  9. YouTube

    Tempus AI 60% Rocket! Buy TEM Stock Now! TEM Stock Analysis

    Ez Money Show analyzes Tempus AI stock, discussing its potential as a portfolio investment.

    Channel
    Ez Money Show
    Views
    23
    Comments
    0
    Tags
    Stock Analysis, Biotechnology, Precision Medicine

    YouTube (Ez Money Show)

  10. Website changes · Product launch

    No new products, services, or major feature launches are indicated in the recent website update.

    The content remains focused on existing solutions, clinical data, and integration capabilities without mention of new offerings.

    Page
    /oncology

    tempus.com

Showing 10 of 70+ signals. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track Tempus AI with the Signal API

One POST /v1/companies/enrich call with tempus.com returns Tempus AI signals from 14 more signal types (reddit-company, podcast-company, glassdoor-company and more), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{
    "domain": "tempus.com",
    "signal_types": ["reddit-company","podcast-company","glassdoor-company",
      "product-reviews","linkedin-post-company","twitter-company-posts",
      "youtube-company","website-intelligence","patents-company",
      "federal-contract-award","conference-speaker","hackernews",
      "producthunt-launch","seo-traffic"],
    "limit": 20
  }'

Bulk data

Need these signals for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file).

Talk to sales

Company pages

Questions about Tempus AI other signals

What signals does Autobound track for Tempus AI besides news and filings?
This page lists 70+ signals for Tempus AI from 7 sources: Glassdoor (15+), LinkedIn (15+), Website changes (15+), YouTube (12), Patents (6), Reddit (4) and Product reviews (3). Every row is dated, and most link to the post, review or record.
What are people saying about Tempus AI online?
The newest posts on this page: Aug 28, 2026, Reddit (r/wallstreetbets): Tempus has an agreed buyout offer to acquire Personalis at $16.25 per share, which is pending shareholder approval. Aug 28, 2026, Reddit (r/Stoxcraft): Tempus AI agreed to acquire genomic sequencing company Personalis for roughly $1.5B. Aug 24, 2026, Reddit (r/StockTitan): Tempus received FDA clearance for its AI product designed to detect signs of pulmonary hypertension from standard ECGs.
What do employees say about working at Tempus AI?
The newest Glassdoor theme on this page, dated Oct 10, 2026: Employees report low associate pay and compensation below market rate. The overall rating in that row is 3.1 of 5. Themes summarize recent reviews; read the reviews on Glassdoor for the full picture.
Has Tempus AI been granted patents recently?
Yes. The newest grant on this page: Oct 27, 2026, Patents (Google Patents): Tempus AI was granted a patent for extracting clinical phenotypes from notes.

Page updated , the date of the newest row on this page.

Source. Reddit, podcasts, Glassdoor, product reviews, LinkedIn, X, YouTube, company websites, patents, federal contracts, conference talks, Hacker News, Product Hunt, web traffic and employee growth, from the Signal API.

Method. The latest 15 signals per source from the last 12 months. Posts that do not name the company, replies, repeats and unreadable rows are removed. Traffic and headcount keep their newest measure.

Data as of .

How this data is built →Get it from the Signal API →